Trilaciclib plus chemo for new DLBCL patients
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether adding a drug called trilaciclib to standard chemotherapy can help people with newly diagnosed Diffuse Large B-Cell Lymphoma. It aims to see if this combination keeps blood counts healthier and improves treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a new diagnosis of Diffuse Large B-Cell Lymphoma (a type of blood cancer) that hasn't been treated yet.
- You must be in generally good health to receive the study treatment.
- You cannot have other active cancers or serious health problems like uncontrolled heart disease.
- Women who can have children must have a negative pregnancy test and agree to use birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called Lisatoclax added to standard chemotherapy (R-CHOP or Pola-R-CHP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better and is safe.
This trial tests a new drug called TRS005 combined with standard chemotherapy (cyclophosphamide, doxorubicin, and prednisone) for people who haven't yet been treated for a type of lymphoma called CD20-positive DLBCL. The goal is to see if adding TRS005 helps more people get better.
This trial tests a new drug called birelentinib combined with standard chemotherapy (R-CHOP) for people who have just been diagnosed with a type of lymphoma called DLBCL. The goal is to see if the combination works better than R-CHOP alone.
This trial tests a new drug called TQB2825 combined with chemotherapy for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least one prior treatment. It aims to see if this combination can help when other treatments haven't worked and stem cell transplant is not an option.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a new drug combination for people with locally advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if adding trilaciclib to standard chemo and immunotherapy works better before surgery.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.